Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,564 shares of the company's stock, valued at approximately $301,000.
Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after purchasing an additional 568 shares during the period. Lazard Asset Management LLC purchased a new position in Kiniksa Pharmaceuticals International during the 4th quarter worth $61,000. KLP Kapitalforvaltning AS purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $158,000. Bellevue Group AG purchased a new position in shares of Kiniksa Pharmaceuticals International in the 4th quarter valued at $160,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Kiniksa Pharmaceuticals International by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock valued at $168,000 after acquiring an additional 4,575 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.
Kiniksa Pharmaceuticals International Price Performance
KNSA traded up $1.59 on Wednesday, reaching $28.80. 908,924 shares of the stock were exchanged, compared to its average volume of 556,641. The company's 50-day moving average price is $27.65 and its 200 day moving average price is $23.00. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $30.69. The firm has a market capitalization of $2.10 billion, a PE ratio of -115.20 and a beta of 0.05.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company had revenue of $137.79 million during the quarter, compared to analysts' expectations of $128.35 million. During the same quarter in the previous year, the firm posted ($0.25) EPS. The firm's revenue was up 72.5% compared to the same quarter last year. As a group, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Mark Ragosa sold 21,254 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $26.95, for a total value of $572,795.30. Following the completion of the transaction, the chief financial officer owned 27,009 shares of the company's stock, valued at $727,892.55. The trade was a 44.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Eben Tessari sold 45,042 shares of the business's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.51, for a total value of $1,374,231.42. Following the completion of the transaction, the chief operating officer directly owned 72,363 shares of the company's stock, valued at approximately $2,207,795.13. This trade represents a 38.36% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 440,863 shares of company stock worth $12,101,029. 53.48% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of research analysts have recently issued reports on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush reiterated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday. Finally, Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of "Buy" and a consensus price target of $39.33.
Read Our Latest Report on Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Company Profile
(
Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Stories

Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.
While Kiniksa Pharmaceuticals International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.